These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
438 related articles for article (PubMed ID: 19155250)
1. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Galiè N; Manes A; Negro L; Palazzini M; Bacchi-Reggiani ML; Branzi A Eur Heart J; 2009 Feb; 30(4):394-403. PubMed ID: 19155250 [TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Ryerson CJ; Nayar S; Swiston JR; Sin DD Respir Res; 2010 Jan; 11(1):12. PubMed ID: 20113497 [TBL] [Abstract][Full Text] [Related]
3. Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension: A systematic review and meta-analysis. Zhang HD; Zhang R; Jiang X; Sun K; Wu DC; Jing ZC Am Heart J; 2015 Jul; 170(1):96-103, 103.e1-14. PubMed ID: 26093869 [TBL] [Abstract][Full Text] [Related]
4. Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials. Zheng YG; Ma H; Hu EC; Liu G; Chen G; Xiong CM Pulm Pharmacol Ther; 2014 Dec; 29(2):241-9. PubMed ID: 25173912 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials. Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870 [TBL] [Abstract][Full Text] [Related]
6. Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes. Zheng Y; Yang T; Chen G; Hu E; Gu Q; Xiong C Eur J Clin Pharmacol; 2014 Jan; 70(1):13-21. PubMed ID: 24026627 [TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase 5 inhibitors for pulmonary hypertension. Barnes H; Brown Z; Burns A; Williams T Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543 [TBL] [Abstract][Full Text] [Related]
8. A meta-analysis of randomized controlled trials in targeted treatments of chronic thromboembolic pulmonary hypertension. Zhang J; Li JM; Huang ZS; Xu JC; Fan Y Clin Respir J; 2019 Jul; 13(7):467-479. PubMed ID: 31059198 [TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis. Coeytaux RR; Schmit KM; Kraft BD; Kosinski AS; Mingo AM; Vann LM; Gilstrap DL; Hargett CW; Heidenfelder B; Dolor RJ; McCrory DC Chest; 2014 May; 145(5):1055-1063. PubMed ID: 24371842 [TBL] [Abstract][Full Text] [Related]
10. Endothelin receptor antagonists for pulmonary arterial hypertension. Liu C; Chen J; Gao Y; Deng B; Liu K Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD004434. PubMed ID: 23450552 [TBL] [Abstract][Full Text] [Related]
11. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials. Avouac J; Wipff J; Kahan A; Allanore Y Ann Rheum Dis; 2008 Jun; 67(6):808-14. PubMed ID: 17901091 [TBL] [Abstract][Full Text] [Related]
12. Combination therapy in pulmonary arterial hypertension: a meta-analysis. Bai Y; Sun L; Hu S; Wei Y Cardiology; 2011; 120(3):157-65. PubMed ID: 22212696 [TBL] [Abstract][Full Text] [Related]
13. Endothelin receptor antagonists for pulmonary arterial hypertension. Liu C; Chen J; Gao Y; Deng B; Liu K Cochrane Database Syst Rev; 2009 Jul; (3):CD004434. PubMed ID: 19588356 [TBL] [Abstract][Full Text] [Related]
14. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis. Li Q; Kuang HY; Wu YH; Lu TW; Yi QJ Medicine (Baltimore); 2019 May; 98(20):e15632. PubMed ID: 31096477 [TBL] [Abstract][Full Text] [Related]
15. Clinical trials using vasodilators in pulmonary arterial hypertension: where do we go from here? Macchia A; Mariani J; Comignani PD; Tognoni G Rev Recent Clin Trials; 2011 Sep; 6(3):228-34. PubMed ID: 21682677 [TBL] [Abstract][Full Text] [Related]
16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
17. Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies. Keir GJ; Walsh SL; Gatzoulis MA; Marino PS; Dimopoulos K; Alonso R; Raposeiras-Roubin S; Renzoni EA; Maher TM; Wells AU; Wort SJ Sarcoidosis Vasc Diffuse Lung Dis; 2014 Jul; 31(2):82-90. PubMed ID: 25078636 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of Macitentan in Patients With Eisenmenger Syndrome. Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N; Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694 [TBL] [Abstract][Full Text] [Related]
19. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Gabler NB; French B; Strom BL; Palevsky HI; Taichman DB; Kawut SM; Halpern SD Circulation; 2012 Jul; 126(3):349-56. PubMed ID: 22696079 [TBL] [Abstract][Full Text] [Related]